CB2 receptor protects fatty liver by antifibrogenic and anti‐inflammatory signals, while CB1 increases fatty acid synthesis in HFD‐induced NAFLD (Mallat et al., 2011; Osei‐Hyiaman et al., 2005). Here, CNR1 is linked to metabolic dysfunction-associated steatotic liver disease.